Principal Investigators: Robert Schneider, PhD
EnB Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with cancer and other diseases. The company is developing a pipeline of potential drugs that target various cellular pathways involved in cancer, including programs focused on immune-oncology and targeted therapies. EnB’s lead program, ENB-003, is a small molecule inhibitor of the Wnt signaling pathway, which is dysregulated in many types of cancer. The company is also developing other potential therapies that target cellular processes involved in cancer progression, including tumor angiogenesis and cell proliferation.